BlackRock Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

BlackRock Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.52M	Buy	219,108 +2,047	+0.9%	+$14.1K	﹤0.01%	2405
2016 Q3	$1.79M	Buy	217,061 +40,230	+23%	+$340K	﹤0.01%	2243
2016 Q2	$1.43M	Buy	176,831 +16,975	+11%	+$107K	﹤0.01%	2379
2016 Q1	$812K	Buy	159,856 +3,136	+2%	+$17.2K	﹤0.01%	2621
2015 Q4	$1.21M	Buy	156,720 +1,447	+0.9%	+$10K	﹤0.01%	2455
2015 Q3	$894K	Sell	155,273 -3,372	-2%	-$26.3K	﹤0.01%	2673
2015 Q2	$1.46M	Buy	+158,645	New	+$1.77M	﹤0.01%	2480

Other funds holding IOVA

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Investment Management's IOVA Position: Q4 2016 in Review

BlackRock Investment Management increased its Iovance Biotherapeutics (IOVA) stake by 0.94% in Q4 2016, buying an estimated $14.1K and bringing the position to 219,108 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2405.

BlackRock Investment Management first reported a position in IOVA in Q2 2015 and has held it in 7 quarters since. The position peaked at $1.79M in Q3 2016. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2016.

BlackRock Investment Management held 219,108 shares of Iovance Biotherapeutics worth $1.52M as of Q4 2016.
BlackRock Investment Management bought 2,047 Iovance Biotherapeutics shares in Q4 2016, an estimated $14.1K.
Iovance Biotherapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2405 holding.
BlackRock Investment Management first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Investment Management's Iovance Biotherapeutics position peaked at $1.79M in Q3 2016.
87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.